EORTC Bladder Cancer Recurrence and Progression Calculator

The European Organisation for Research and Treatment of Cancer (EORTC) scoring system relies on weighted clinical and pathological parameters. For recurrence, points are assigned based on the number of tumors, tumor diameter, prior recurrence rate, category (stage), presence of concurrent CIS, and tumor grade. Similarly, a separate point system calculates the progression risk using the same core variables weighted differently. Total points for recurrence and progression are mapped against validated actuarial tables to determine the exact 1-year and 5-year percentage probabilities.

Consider a patient presenting with multiple papillary tumors (greater than 3 cm), a high prior recurrence rate, stage T1 disease, presence of concurrent carcinoma in situ (CIS), and high-grade pathology. 1. Recurrence Scoring: Summing the assigned points for multiple tumors (3), size > 3cm (3), high prior rate (2), T1 stage (3), CIS present (1), and high grade (1) yields a total recurrence score of 13 points. 2. Progression Scoring: Following the progression-specific point matrix, the patient accumulates points for multiple tumors (2), size > 3cm (3), prior rate (2), T1 stage (4), CIS (3), and high grade (3), totaling 17 points. 3. Risk Output: Consulting the EORTC risk tables, a recurrence score of 13 corresponds to a high 1-year and 5-year recurrence risk profile, while a progression score of 17 places the patient in the high-risk category for disease advancement, requiring rigorous follow-up cystoscopy and potential adjuvant therapies.

Verify Pathology Reports: Ensure that tumor grade (WHO 1973 or WHO/ISUP 2004) and exact pathological staging (Ta, T1, CIS) are precisely entered, as minor categorization shifts drastically alter point totals. Consult Your Urologist: Risk scores are statistical averages and should be interpreted alongside individual patient health factors, comorbidities, and specialized urological imaging or biomarker testing.